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Abstract  
 
Background: Acute Lymphoblastic Leukemia (ALL) is the most common cancer in children, 
represents approximately 75–80% of acute leukemia. Global incidence is about 3-4 cases per 
100,000 population under 15 years old. Researches about pediatric ALL in Palestine are limited. 
This study provides the immunophenotyping of pediatric ALL patients at a single cancer center 
experience in southern west bank area in Palestine. 
Objectives: The main objectives of this study are to characterize the immunophenotypic pattern 
of pediatric ALL subtypes among Palestinians, highlight the importance of some clinical features 
according to age and immunophenotypic pattern in patients prognosis and response to treatment, 
and to determine the response to therapy after induction phase using the minimal residual disease 
(MRD) in time point 1 (day 33). 
Materials and Methods: This study is an incident study, was conducted from January 2015 to 
December 2015 at Huda Al-Masri pediatric cancer department at Beit-Jala hospital, which is 
located in the southern area of west bank in Palestine. A total of 15 consecutive children (7 
females, 8 males) < than 14 years with newly diagnosed ALL were selected by pediatric 
oncologists at Huda Al-Masri pediatric cancer department at Beit-Jala hospital, this hospital is 
one of the largest pediatric centers for leukemia patients in Palestine. 
Archived data of pediatric ALL patients in their medical files were reviewed with ethical 
consideration of patient privacy to obtain some clinical features of the given patient. 
All cases either retrospective or incident were tested by College of American Pathologists (CAP) 
accreditation pathology department at King Hussein Cancer Center (KHCC) in Amman-Jordan 
on bone marrow aspirate samples collected in Ethylenediaminetetraacetic acid (EDTA) tubes 
according to a two step strategy using panels of monoclonal antibodies based on European Group 
for Immunological Characterization of Leukemia (EGIL). For the study purpose, the 
immunophenotyping of the incident target cases at 2015 was performed at Huda Al-Masri 
pediatric cancer department at Beit-Jala hospital in Bethlehem on bone marrow aspirate samples 
collected in EDTA tubes according to a two step strategy using Flow Cytometer, and for 
validation purpose, the achieved results were compared with the KHCC results of the same cases 
and no significant difference was noted. 
  
Minimal Residual Disease results were evaluated by examining the most common antigens or CD 
markers through reactivity of fluorescent conjugated monoclonal antibodies directed against 
lymphoid associated antigens for each ALL type on the surface of bone marrow cells after the 
induction point 1 at day 33 of treatment by flow cytometry technique. 
 
Results: Statistical analysis of the results was performed, and the study group comprised 15 
newly diagnosed acute lymphoblastic leukemia cases (<14 years). There were 7 females and 8 
males with a male/female ratio of 1.14:1. The age distribution of the precursor B-cell ALL 
subtype showed that precursor B-cell ALL patients were younger with peak incidence between 2 
and 5 years. Geographical distribution of Palestinian pediatric ALL showed that about half of the 
cases (46.7%) from Hebron governorate, but with the same percentage of cases diagnosed in 
Bethlehem governorate depending on the number of inhabitants. 
 
Immunophenotyping analysis showed that the precursor B-cell phenotype was encountered in 14 
(93.3%) cases, mature B-cell in Zero (0%) cases, and T-cell in 1 (6.7%) case. Lineage 
Heterogeneity was found only in precursor B-cell ALL cases having one or two myeloid 
associated antigens (CD13,CD33) expressed on their blast cells. Lineage Heterogeneity for both 
antigens was found in 7.1% of precursor B-cell ALL cases. 
 
By the examining of MRD, we found that 13 of pediatric ALL cases (86.7%) were subjected to 
complete remission after the end of induction point 1 at day 33 with the only case of T-cell ALL 
and 85.7% of precursor B-cell ALL cases, but not statistically significant. 
 
Conclusion: This study is a unique study providing a clear idea about the munophenotyping of 
pediatric ALL cases at a single cancer center experience in southern west bank area in Palestine, 
and this immunophenotypic distribution was similar to the general immunophenotypic 
distribution pattern in developed countries. The age distribution showed a peak incidence 
between 2 and 5 years among the precursor B-cell ALL subtype as in developed countries. 
Geographical distribution of Palestinian pediatric ALL showed that about half of the cases 
(46.7%) from Hebron governorate, but with the same percentage of cases diagnosed in 
Bethlehem governorate depending on the number of inhabitants.  
The response to treatment for ALL patients was very good as in developed countries, due to the 
negative MRD at the end of induction point 1 at day 33 was 86.7% of ALL patients. 
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Chapter one   
 
Introduction 
 
1.1. Background  
 
Acute lymphoblastic leukemia (ALL) is a type of leukemia which is characterized by 20% or 
more lymphoblasts in the bone marrow. It is a rapidly developing, abnormal growth of the cells 
that are precursors of lymphoblasts (Neelkamal et al., 2013). 
Acute lymphoblastic leukemia is the most common malignancy in children and represents 75–
80% of acute leukemia. The incidence of pediatric ALL is about 3–4 cases per 100,000  under 15 
years old. Although it affecting children of all ages, the incidence peaks between two and five 
years of age with a slightly higher among males over females (de Sousaa et al., 2015).  
ALL arise from B-cell in 85% patients and from T-cell in 15% cases. However, B-cell leukemia 
occurs more frequently than T-cell leukemia as you seen in Figure 1.1 (Neelkamal et al., 2013, 
and Hunger and Mullighan, 2015). It is the most common type of leukemia found in children, 
nearly 75% of cases occur in children under six years of age (Neelkamal et al., 2013). 
 
Figure 1.1: Percentage frequency of cell type in children of acute lymphocytic leukemia. 
  
B-cell and T-cell lymphoblastic leukemia cells express surface antigens that parallel their 
respective lineage developments. Precursor B-cell ALL cells typically express CD10, CD19, and 
CD34 on their surface along with nuclear terminal deoxynucleotide transferase (nTdT), while 
precursor T-cell ALL cells commonly express CD2, CD3, CD7, CD34, and nTdT (Neelkamal et 
al., 2013). Usually T-lineage ALL is diagnosed in male adolescents and is frequently 
characterized by high white blood cells count at diagnosis, older age, mediastinal mass, and 
central nervous system involvement. Furthermore, children with T-ALL generally have a poorer 
prognosis than those with precursor B-lineage ALL (Goldberg et al., 2003; and Willemse et al., 
2002). 
Since the first description in 1948 of temporary remission of leukemia induced by chemotherapy, 
children of ALL has provided a model for refinement of survival among patients with cancer by 
progressive improvements in the efficacy of multi-agent chemotherapy regimens and by 
stratification of treatment intensity according to the clinical features of the patient, the biologic 
features of the leukemia cells, and the early response to treatment which are predictive of the risk 
of relapse. These advances have increased the survival rate from less than 10% in the 1960s to 
90% nowadays (Figure 1.2) (Hunger and Mullighan, 2015). 
 
Figure 1.2: Overall survival among children with acute lymphoblastic leukemia, 1968-2009. 
  
The survival rate of children ALL patients has improved to approximately 90% in recent years, 
especially for groups with good prognosis. This progress is mainly due to the stratification of 
patients into different risk groups. Stratification into risk groups is based on a range of clinical, 
and biological features such as age, gender, white blood cell (WBC) count at diagnosis, 
immunophenotype, and early response to induction therapy (de Sousaa et al., 2015).  
Early response to treatment determined by the level of minimal residual disease (MRD) at the 
end of induction therapy (day 33) is actually the most important prognostic factor in patients 
with ALL (de Sousaa et al., 2015). 
In a study at the time of morphologic remission at time point 1 at 5 weeks of treatment, 80%  of 
patients with T-ALL were still MRD positive in contrast to 54%  patients with precursor B-ALL. 
However, this study showed that MRD analysis allows a highly accurate prediction of clinical 
outcome within the 2 major immunophenotypic ALL categories (Willemse et al., 2002).   
Nevertheless, the number of MRD positive patients and its level were higher in T-ALL than in 
precursor B-ALL, reflecting the more frequent occurrence of resistant disease in T-ALL patients 
(Willemse et al., 2002). 
Furthermore, 23% of patients with T-ALL and 46% of patients with precursor B-ALL were 
classified in the low risk group, and had a 5-year relapse free survival rate of 98% or greater. In 
contrast, 28% of patients with T-ALL were classified in the MRD based high risk group 
compared to just 11% of patients with precursor B-ALL, and the relapse free survival rates were 
0% and 25%, respectively (Willemse et al., 2002).  
In another study on precursor B-ALL, 5-year event free survival was >90%. Therefore, MRD 
negativity at the end of induction point 1 at day 33 is the strongest predictor for excellent clinical 
outcome (Conter et al., 2009). 
Minimal residual disease is a powerful predictor of the overall response (clinical outcome) of 
treatment in children ALL. The most reliable and validated methods to estimate MRD in ALL 
are flow cytometric analysis of leukemia associated immunophenotypes and polymerase chain 
reaction (PCR) amplification of antigen receptor gene rearrangements (Gaipa et al., 2013). 
The causative factors of acute lymphoblastic leukemia may be like smoking, high birth weight, 
diet, and high socioeconomic status, electromagnetic field, being exposed to ionizing radiation, 
  
pesticides, past treatment with chemotherapy or other drugs that weaken the immune system 
(Neelkamal et al., 2013). 
 
Demonstration of seasonal variation in the incidence of acute lymphoblastic leukemia may 
provide insight into potential risk factors. Although the etiology of acute lymphocytic leukemia  
in pediatric remains largely unknown, hypotheses relating to a viral infections have gained 
support in recent years because viral infections have seasonal variations of onset (Badrinath et 
al., 1997, and Karimi and Yarmohammadi, 2003). 
There have been a number of reports on the seasonality of leukemia, but the results are 
inconsistent due to some studies reported a significant late spring/early summer excess in the 
onset of leukemia, and another studies found an excess acute lymphoblastic leukemia patients in 
late autumn/early winter. However, several studies failed to demonstrate any significant 
seasonality in the onset of acute lymphoblastic leukemia cases (Badrinath et al., 1997, and 
Karimi and Yarmohammadi, 2003). 
 
1.2. Acute lymphoblastic leukemia in the United States 
 
ALL is the most common cancer among children and the most frequent cause of death from 
cancer before 20 years of age. Approximately 6000 cases of ALL are diagnosed in the United 
States annually, half of the cases occur in children and teenagers (Ward et al., 2014 and Hunger 
and Mullighan, 2015). 
The incidence of ALL is about 30 cases per million persons younger than 20 years of age, with 
the peak incidence between 3 to 5 years of age, and develops more frequently in males than in 
females with (male: female ratio of 55% to 45%) (Hunger and Mullighan, 2015). 
 
 
 
1.3. Acute lymphoblastic leukemia in the Middle East  
 
  
In the Middle East, precursor B-cell ALL represented 84.2% and T-cell ALL represented 14.8% 
with 47.1% in low/standard risk, 16.9% with intermediate risk, and 36% with high risk according 
to clinical criteria. The peak age range at diagnosis between 3-6 years is similar to the ALL 
reported from the west with gender ratio of male to female (1.4:1) that may be slightly higher 
than reported from the west (AL-Mulla et al., 2014). Children had excellent induction response 
to chemotherapy with an overall complete remission rate of 96% (AL-Mulla et al., 2014).  
 
However, the immunophenotypic distribution of ALL subtypes in the Middle East is similar with 
the general distribution pattern in developed countries (AL-Mulla et al., 2014). 
 
 
1.4. Acute lymphoblastic leukemia in Palestine 
  
The number of reported acute lymphoblastic leukemia cases in children by hospitals in West 
Bank in Palestine between 2009 to 2015 was 119 cases. However, 68 cases were registered at 
Huda Al-Masri pediatric cancer department at Beit-Jala Hospital. The number of reported acute 
lymphoblastic leukemia deaths in these Hospitals at west bank in Palestine from 2009 to 2015 
was 9 cases, with a mortality rate of 7.6 per 100 (Palestinian Health Information Center, 2015). 
 
There was a possibility that the immunological subtypes of pediatric acute lymphoblastic 
leukemia could include high risk of leukemia subtypes. To our knowledge, immunophenotyping 
analysis, clinical features, and risk stratification have not been previously tested in Palestine in 
previous studies. 
 
1.5. Problem statement 
Cancer incidence rates in Palestine have been increased; in addition, cancer has become the 
second leading cause of death. Leukemia has been reported to be the fourth most common cancer 
among Palestinians in the west bank both in 2014 and 2015 with ALL is the most common 
cancer among children. Many clinical and immunophenotypic characteristics have been 
identified as having prognostic significance in the outcome of patients with ALL, yet have never 
been studied in Palestine. In this study, we explored the clinical and immunophenotype pattern 
among children ALL patients diagnosed on 2015 at Huda Al-Masri pediatric cancer department 
at Beit-Jala Hospital; one of the largest oncology centers in Palestine.  
  
1.6. Justification of the study  
ALL has been associated with high morbidity and mortality among children worldwide and in 
Palestine. The clinical and the immunophenotype pattern of pediatric ALL have never been 
investigated among Palestinians although they are postulated to be associated with patients 
prognosis and complete remission of leukemia. 
1.7. Study Questions 
 
1:What are the clinical and the immunophenotypic characteristics of Palestinian pediatric ALL 
patients? 
2: What are their associations with patients prognosis and complete remission of leukemia? 
 
1.8. Study Aims 
Immunophenotyping of pediatric ALL patients by Multicolor Flow Cytometric Analysis at a 
single cancer center experience in southern west bank in Palestine:  
1: To characterize the immunophenotypic pattern of pediatric ALL subtypes among Palestinians. 
2: To highlight the importance of some clinical features according to age and immunophenotypic 
pattern in patients prognosis and response to treatment. 
3: To determine the response to therapy after induction phase using the MRD in time point 1 
(day 33). 
 
 
 
Chapter two  
 
Literature review 
 
2.1. Background 
 
  
Acute lymphoblastic leukemia is a malignant clonal proliferation of lymphoid progenitor cells 
which differentiate into subtypes B and T, and is a fast growing cancer of a type of white blood 
cells called lymphoblasts (Figure 2.1). These cells are usually found in the bone marrow that 
produces a large number of immature lymphoblasts, prevent healthy blood cells from being made 
and do not work properly to fight infection (National Cancer Institute, 2016).  
 
 
Figure 2.1: Blood cell development.  
A blood stem cell goes through several steps to become a red blood cell, platelet, or white blood 
cell (National Cancer Institute, 2016). 
 
 
 
 
2.2. Epidemiology of acute lymphoblastic leukemia 
 
Annually, almost 3000 children in the United States are diagnosed with ALL, with annual 
incidence 3.7-4.9 cases per 100,000 children between 0-14 years of age with a similar estimated 
worldwide incidence (Ribera and Oriol, 2009). However, the improvements in diagnosis and 
treatment, overall survival rates for children with acute lymphoblastic leukemia have reached 
90% (Hunger et al., 2012). 
  
As explained by the following studies, it appears that the  incidence of pediatric leukemia is 
increasing. In the analysis of Surveillance, Epidemiology, and End Results (SEER) database, 
there was a steady increase in ALL incidences from 1975 to 2010 with an average annual 
increase in incidence of almost 0.7 percent (Howlader et al., 2013). However, the estimated 
incidence increased from 25 cases per million in 1975 to 34 cases per million in 2010 (Ward et 
al., 2014). 
Another study that used data from 63 European population based cancer registries of children 
diagnosed with cancer, the incidence of leukemia including ALL increased by a rate of 1.4 
percent from 1970 to 1999 (Steliarova-Foucher et al., 2004). In Great Britain, the incidence of 
leukemia mostly attributable to ALL  has steadily increased from 3.83 to 4.61 per 100,000 
persons by sex and age from the five year period of 1971 to 1975 and 1996 to 2000 (Shah and 
Coleman, 2007).  
 
On the other hand, a study from four Nordic countries (Denmark, Finland, Norway and Sweden)  
recorded that the incidence of pediatric ALL stayed stable at an approximate rate of 3.3 cases per 
100,000 pediatrics below 15 years of age from 1983 to 2002 after an increase in incidence 
between 1975 and 1983 (Svendsen et al., 2007). 
 
From 1992 to 2011, the incidence rate for acute lymphoblastic leukemia increased significantly 
among both Hispanic children and non-Hispanic children in USA as you see in Figure 2.2 
(Howlader et al., 2013). 
 
  
 
Figure 2.2: Age adjusted incidence rates of pediatric acute lymphocytic leukemia by ethnicity, 
SEER 13, 1992-2011. 
 
The incidence of ALL appears to be highest in Hispanic children (43 cases per 1 million), and 
the incidence is substantially higher in white children than in black children, with a nearly three 
fold higher incidence of ALL from age 2 to 3 years in white over the black (National Cancer 
Institute, 2016). 
However, there is no published data was found to explain the prevalence of pediatric ALL in 
Palestine. 
 
2.3. Early clinical signs and  symptoms of ALL  
 
The most common presenting symptoms of ALL are nonspecific such as loss of appetite and 
weight loss, fever, night sweats, bleeding, bone pain, and lymphadenopathy (Margolin et al., 
2001 and National Cancer Institute, 2016). Unexplained existence of any of these common signs or 
symptoms should be immediately considered of malignancy.  
The most common presenting signs or symptoms of leukemia that are revealing of malignancy 
are: 
  
 
1.Musculoskeletal pain: Early bone marrow screening should be considered in any child who has 
existence bone pain and peripheral blood abnormalities. Bone pain, specifically affecting the 
long bones and caused by leukemic involvement of the periosteum, is a presenting symptom in 
21 to 38 percent of cases of acute leukemia (Rogalsky et al., 1986; Jonsson et al., 1990 and 
Sinigaglia et al., 2008).  
2.Headache: Although uncommon in less than 5 percent of cases, leukemia involving the central 
nervous system (CNS) can exist with symptoms of increased intracranial pressure, including 
headache, vomiting, lethargy, and or nuchal rigidity (Bleyer, 1988, and National Cancer Institute, 
2016). 
3.Lymphadenopathy: Lymphadenopathy associated with malignancy usually is non-tender, firm, 
rubbery, and matted. Almost 50 percent of pediatric ALL exist with lymphadenopathy, which is 
considered to be one of the indications of extramedullary leukemic spread (Margolin et al., 2001, 
and National Cancer Institute, 2016). 
4.Testicular enlargement: Although it is very rare, painless unilateral testicular enlargement can 
be a presenting sign of ALL. The persistent of painless solid testicular mass should be referred 
for biopsy by a pediatric surgeon after evaluation by ultrasound (National Cancer Institute, 2016). 
5.Mediastinal mass: T-cell ALL commonly occurs in older boys (≥10 years old) who present 
with high initial white blood cell (WBC) counts (≥50,000/ul) and a large mediastinal mass 
(Margolin et al., 2001 and National Cancer Institute, 2016).  
6.Peripheral blood abnormalities: Most pediatric ALL have anemia, thrombocytopenia with 
either normal or slightly increased WBC counts and lymphoblasts on peripheral smear (Chiaretti 
et al., 2013). Almost 50 percent of pediatric ALL have WBC counts <10,000/ul, and 20 percent 
have an initial WBC count >50,000/ul (Margolin et al., 2001 and Chiaretti et al., 2013). 
Furthermore, one-half of pediatric ALL have bleeding (including petechiae and purpura), and 
three quarters have a platelet count <100,000/ul at the time of diagnosis (Margolin et al., 2001).  
 
 
 
2.4. Classical laboratory tests and clinical procedures for ALL 
 
ALL can present clinically as either a mass lesion or as leukemia. Although the difference  in 
some patients is qualitative, ALL is the preferred term when the bone marrow contains more than 
  
25 percent lymphoblasts, whereas lymphoma is the best term when the process is restricted to a 
mass lesion with minimal or no blood and bone marrow involvement (Brunning et al., 2001).  
 
The diagnosis and classification of leukemia by using specialized tests that are performed on 
cells derived from a bone marrow aspirate or tissue biopsy specimens. When clinical situations 
excludes bone marrow examination, the diagnosis can be occur from cells obtained from the 
peripheral blood or pleural effusions to diagnose ALL and find out if leukemia cells have spread 
to other parts of the body such as the brain or testicles (Margolin et al., 2001 and National Cancer 
Institute, 2016). 
 
A physical exam that may detect bruising, hepatosplenomegaly (Swollen of  liver or spleen), 
swollen of lymph nodes, and petechiae or purpura. Complete Blood Count (CBC) test that 
measures the number of red blood cells and platelets, the number and type of white blood cells, 
the amount of hemoglobin in the red blood cells, and the portion of the sample made up of red 
blood cells. Blood chemistry tests that used to measure the amounts of certain substances 
released into the blood by organs and tissues in the body. An uncommon either higher or lower 
than normal amount of a substance can be a sign of disease. Bone marrow aspiration for flow 
cytometry diagnosis and biopsy for morphological diagnosis of leukemic cells (National Cancer 
Institute, 2016). 
 
Several tests used to characterize and stratify leukemic cells such as immunophenotyping test 
and molecular cytogenetic test. Immunophenotyping analysis that used antigens or markers on 
the surface of a bone marrow cells are characterized into lymphoid cells or myeloid cells, and 
then if the cells are malignant lymphocytes, they are also distributed into B lymphocytes or T 
lymphocytes by these specific antigens.  
Molecular cytogenetic analysis used to characterize the changes of chromosomes in the 
lymphocytes under an microscope. For instance, in Philadelphia chromosome positive ALL, part 
of one chromosome is replaced to another chromosome (National Cancer Institute, 2016). 
 
Another tests such as Fluorescence In Situ Hybridization (FISH) may also be used to diagnose 
certain changes in the chromosomes (Margolin et al., 2001). Moreover, another tests used to 
detect relapse and metastasis of  leukemic cells such as lumbar puncture test, chest X-ray test, 
and testicular biopsy test (National Cancer Institute, 2016).  
  
 
2.5. Differential diagnosis 
  
A different malignant and nonmalignant situations must be considered in the differential 
diagnosis of ALL, because the existing signs and symptoms are nonspecific. They include 
(Simone et al.,1975 and Margolin et al., 2001): 
 
 Juvenile idiopathic arthritis. 
 Osteomyelitis. 
 Epstein-Barr virus. 
 Immune thrombocytopenia (ITP). 
 Aplastic anemia. 
 Acute infectious lymphocytosis. 
 Other malignancies with bone marrow involvement (neuroblastoma, retinoblastoma, 
rhabdomyosarcoma, and Ewing sarcoma). 
 Hypereosinophilic syndrome. 
 
2.6. Pathological features of ALL 
 
Historically, ALL has been classified morphologically using the French-American-British (FAB) 
system that integrates information regarding the size, amount of cytoplasm, and importance of 
nucleoli of tumor cells from the bone marrow aspirate (Bennett et al., 1976 and National Cancer 
Institute, 2016). 
Nevertheless, some clinicians still use this system to characterize and describe the phenotype of 
the tumor cells, but it has lost its prognostic value as our knowledge of disease biology has 
improved and treatment regimens have begin to be more intense and successful. However, FAB 
criteria is not currently used in either diagnosis or treatment decisions (Bennett et al., 1976 and 
National Cancer Institute, 2016). 
 
According to the FAB system: 
 
  
●L1 lymphoblasts are small cells with weak cytoplasm, condensed nuclear chromatin, and 
unclear nucleoli (Figure 2.3). Most pediatric ALL cases almost 85 to 89 percent are classified as 
having FAB L1 (Miller et al., 1981 and Lilleyman et al., 1992). 
 
Figure 2.3: L1 morphology of bone marrow aspirate from a patient with ALL. 
 
●L2 lymphoblasts are larger cells with a moderate amount of cytoplasm, dispersed chromatin, 
and multiple nucleoli (Figure 2.4). In several studies, L2 has been correlated with poor prognosis 
than has L1 (Miller et al., 1981 and Lilleyman et al., 1986). While, when patients are stratified 
according to age, sex, and initial WBC, differences in prognosis between L1 and L2 are no 
longer observed (Lilleyman et al., 1992). Eleven to fourteen percent of cases of pediatric ALL 
are classified as FAB L2 (Miller et al., 1981 and Lilleyman et al., 1992).  
  
 
Figure 2.4: L2 morphology of bone marrow aspirate from a patient with ALL. 
 
●L3 lymphoblasts have deep cytoplasmic basophilia with distinct cytoplasmic vacuolation 
(Figure 2.5). L3 morphology relates with a more guarded prognosis. However, less than 1 
percent of cases of pediatric ALL are classified as FAB L3 (Miller et al., 1981 and Lilleyman et 
al., 1992). 
 
 
Figure 2.5: L3 morphology of bone marrow aspirate from a patient with ALL. 
2.7. Immunophenotyping of ALL 
  
 
FAB classification of ALL has been modified by the World Health Organization (WHO) 
depending on immunophenotyping using an extensive panel of monoclonal antibodies to cell 
surface "cluster of differentiation" (CD) markers (Chiaretti et al., 2014). 
 
Immunophenotyping by means of multi channel flow cytometry has become the standard 
procedure for ALL diagnosis and sub-classification. It was also developed as useful tool for the 
detection and monitoring of minimal residual disease. The consensus by European Group for the 
Immunological characterization of leukemia (EGIL) is that a threshold of 20% should be used to 
define a positive reaction of blast cells to a given monoclonal antibody, except for 
myeloperoxidase (MPO), CD3, CD79a and nTdT, which are considered positive at the 10% level 
of expression, and 30% or more for myeloid markers such as CD33, and CD13 (Chiaretti et al., 
2014). 
 
The cases were classified into four main ALL immunological subtypes: precursor B-cell ALL 
that constitutes about 80% of cases, mature B-cell ALL that constitutes about 2-5% of cases, 
precursor T-cell ALL, and mature T-cell ALL that constitute about 15-17% of cases (Zipf et al., 
2000). A case was considered precursor B-cell ALL, if the cells expressed cytoplasmic CD79a 
and  Immunoglobulin (Ig), and surface CD19, CD10, Human Leukocyte Antigen-D related 
(HLA-DR), CD34 ,CD20, CD22, and nTdT. A case was considered mature B-cell ALL, if the 
cells have also surface Ig expression and clonal lambda or kappa light chains, and negative for 
nTdT and CD34 (Bene et al., 1995 and Chiaretti et al., 2014). 
A case was considered precursor T-cell ALL, if the cells expressed cytoplasmic CD3, and 
surface CD7, CD1a, CD2, CD5,CD4, CD8, CD34, and nTdT. However, it was considered 
mature T-cell ALL, if the cells have also surface CD3, CD4 or CD8, and negative for  CD1a, 
CD34, and nTdT (Bene et al., 1995 and Chiaretti et al., 2014). In T-cell ALL, the expression of 
CD10 is quite common (25%) and not specific (Chiaretti et al., 2014). 
 
 
Furthermore, some B-cell and T-cell ALL also express myeloid markers such as CD13 and 
CD33 in addition to their specific lymphocyte markers (Chiaretti et al., 2014). 
 
  
2.8. Cytogenetics of ALL 
 
Cytogenetic features play an important role in the risk stratification in pediatric ALL. 
Abnormalities concluding both chromosome number and chromosome structure such as gene 
rearrangements and fusions have an effect on patient prognosis (Harrison, 2009).  
 
2.8.1. Numeric abnormalities in ALL:  
 
Numerical abnormalities may influence the whole chromosome set (ploidy changes), or the gain 
or loss of individual chromosomes (aneuploidy changes). The following chromosomal numeric 
abnormalities are prognostic indicators in patients with ALL: 
 
 High hyperdiploidy (50 or more chromosomes) is a suitable prognostic feature, and has 
been uniformly associated with good prognosis in ALL (Rubnitz et al., 2008). Patients 
with high hyperdiploidy, those with the best outcomes in clinical trials from the United 
States include those with either double trisomies of chromosomes 4 and 10, or triple 
trisomies of chromosomes 4, 10 and 17 (Sutcliffe et al., 2005).  
 Hypodiploidy (fewer than 46 chromosomes) is a poor prognostic indicator. The 
probability of a poor outcome increases with a decrease in chromosomal numbers. 
However, hypodiploid cases lacking only a single chromosome have a similar prognosis 
to diploid cases, whereas cases which are near-haploid (24 to 28 chromosomes), have the 
worst outcome (Nachman et al., 2007).  
 Although rare cases with near triploidy (68 to 80 chromosomes) or near tetraploidy (>80 
chromosomes) generally are associated with very poor outcome (Pui et al., 1990), and a 
large series has reported suitable outcome in B-cell lineage cases (Raimondi et al., 2006). 
 
 
 
 
2.8.2. Structural abnormalities in ALL: 
 
Structural gene abnormalities include translocations, deletions, insertions, and inversions. The 
following structural chromosomal abnormalities are prognostic indicators in patients with ALL: 
 
  
 The t(12;21) translocation produces the TEL-AML1 fusion gene. This structural change 
is connected with a suitable prognosis (Shurtleff et al., 2005).  
 The t(9;22) translocation also known as the Philadelphia chromosome: is one of two 
structural rearrangements associated with poor prognosis (Jones et al., 2005). 
 Another rearrangements involving the MLL gene at 11q23 are connected with a poor 
prognosis (Pui et al., 2002). 
 
2.9. Prognostic factors and risk stratification currently used to direct therapy in ALL 
Many clinical, and biological features have been identified as having prognostic significance in 
the clinical outcome of patients with ALL. The standard features are age, gender, WBC count at 
diagnosis, and immunophenotype pattern of the patients, and the most two important prognostic 
factors are age at diagnosis, and the initial WBC count (Friedmann and Weinstein, 2000 and 
Hunger and Mullighan, 2015).  
Infants less than one year, adolescents greater than nine years, and pediatrics with WBC count 
above 50,000/µl being at higher risk. Immunphenotyping of the lymphoblast is highly significant 
prognostic feature, because T-cell and mature B-cell immunophenotypes are associated with a 
very poor prognosis, and precursor B-cell is associated with a good prognosis (Table 2.1) 
(Friedmann and Weinstein, 2000 and Hunger and Mullighan, 2015). 
Table 2.1: Prognostic factors in pediatric acute lymphoblastic leukemia. 
Risk Factor Favorable Outcome Unfavorable Outcome 
Age >1 and <10 years 
 
<1 or >10 years 
Gender Female Male 
WBC count at diagnosis <50,000/ul >50,000/ul 
Immunophenotype Precursor B-cell T-cell, or mature B-cell 
The prognostic value of gender is argumentative, due to some studies report no difference in 
prognosis between males and females, but another centers especially from United Kingdom 
(UK) and Nordic countries have found a significantly higher relapse rate in males over females 
(ARYA, 2004). 
Most of the prognostic factors currently used to determine the intensity of therapy are clinical or 
biological and can be determined at the time of diagnosis. There is great variation in risk 
  
stratification of ALL used by the major clinical trials groups treating pediatric cancer in the 
United State.  Mature B-cell ALL is treated completely differently from precursor B-cell and T-
cell ALL. For the most part, the treatment of precursor B-cell ALL, and sometimes T-cell ALL 
are based on age and WBC at diagnosis as in Table 2.2 that shows the association between age, 
WBC count, and prognosis of pediatrics treated on Pediatric Oncology Group (POG) and 
Children’s Cancer Group (CCG) regimens as of 1993 (Friedmann and Weinstein, 2000). 
Table 2.2: Outcome of 4-year event free survival for children with precursor B-cell ALL treated 
by POG and CCG protocols by multiple age and WBC count categories. 
 Age (years) 
WBC count/ul: 1-2.99 3-5.99 6-9.99 ≥10 
<10,000     
4-year event free survival % 82.9 84.7 82 69.6 
Number of patients treated 490 937 437 406 
% precursor B-cell patients 10.7 20.5 9.6 8.9 
10,000-49,999     
4-year event free survival % 74.6 74.5 80.2 59.2 
Number of patients treated 436 608 205 236 
% precursor B-cell patients 9.5 13.3 4.5 5.2 
≥50,000     
4-year event free survival % 68.3 73.9 47.5 41.1 
Number of patients treated 278 280 122 140 
% precursor B-cell patients 6.1 6.1 2.7 3.1 
 
However, irregularity in the definitions of treatment related risk groups have made it difficult to 
contrast the results of various clinical tests. Due to of this, a workshop was held in 1993 by the 
Cancer Therapy Evaluation Program of the National Cancer Institute (CTEP/NCI) to try to create 
a uniform approach to risk stratification in order to increase the efficiency of clinical research. 
The participating investigators reached an unanimity on the basis of available data that patients 
with precursor B-cell ALL, aged one to nine years, and with WBC count less than 50,000/μl at 
diagnosis which represent the most of patients are at lower risk than other patients (Friedmann 
and Weinstein, 2000 and Schultz et al., 2007).  
  
Table 2.3 shows the four year event free survival for POG and CCG patients at the time of the 
workshop for standard risk group compared to the higher risk group (Friedmann and Weinstein, 
2000).  
Table 2.3: Uniform age and WBC criteria for precursor B-cell ALL standard and high risk 
cohorts adopted at the CTEP/NCI workshop. 
Risk Definition 4-year event free 
survival % 
% of precursor B-cell 
patients  
Standard  WBC count <50,000/ul and age 
1-9.99 years 
80.3 68 
High WBC count ≥50,000/ul or age 
≥10 years 
63.9 32 
 
Nevertheless, current stratification systems use these criteria in addition to several other features 
to stratify patients into treatment groups such as immunnophenotype among different age and 
WBC count groups. For instance, T-cell ALL patients are generally older than precursor B-cell 
ALL patients, partially clarifying the high risk situation of older patients. Similarly, the very 
poor prognostic feature of older patients, tends to present with a higher WBC count (Friedmann 
and Weinstein, 2000 and Schultz et al., 2007).  
Furthermore, extramedullary disease such as in CNS is a factor used to determine the intensity of 
treatment. CNS leukemia is more common in T-cell ALL than precursor B-cell ALL that occurs 
in fewer than 5% of pediatrics at diagnosis, and is generally predictive of a poor treatment 
outcome (Friedmann and Weinstein, 2000 and Hunger and Mullighan, 2015). CNS disease is 
defined as more than five white blood cells per ml of spinal fluid which are blasts 
morphologically. 
However, patients with T-cell ALL are more likely to have unfavorable factors such as male, age 
greater than nine years, high WBC count at diagnosis, low CD10 expression, mediastinal mass, 
and CNS involvement (de Sousaa et al., 2015). 
 
2.10. Treatment of pediatric ALL  
  
 
Improvements in the 5-year survival rate for pediatric ALL continue to be seen by improving 
multiple factors including a better understanding of the immune-biology of ALL and disease 
burden, recognition of shelter sites and integration of pre-symptomatic central nervous system 
prophylaxis, lineation of prognostic factors with risk adapted treatment and improvements in 
supportive care. The overall outcomes are fairly similar, and more than 95% will attain remission 
and close to 85% will survive free of leukemic recurrence at least 5 years from diagnosis (Seibel, 
2008). 
One of the hallmarks of the treatment of pediatric ALL is the dependence on risk based 
stratification by determining the clinical and biological features that have been shown to affect 
prognosis, patients can be classified into groups based on risk of treatment failure. Those with 
favorable clinical and biological features can be treated with the modest therapy to spared 
toxicity, whereas more aggressive regimens are restricted for those with more high risk disease 
to maximize cure. It is therefore fundamental to identify those features shown to consistently 
affect prognosis and influence treatment as in Table 2.4 (Rubnitz et al., 2000; Seibel, 2008 and 
Stacy et al., 2015). 
Successful treatment of pediatric ALL involves administration of a multidrug regimen that is 
divided into several phases (induction, consolidation, and maintenance) and includes therapy 
directed to the CNS. However, most treatment protocols take two to three years to complete. 
(Rubnitz et al., 2000; Seibel, 2008 and Stacy et al., 2015). 
  
Table 2.4: Clinical risk assignment and suggested therapies in pediatric ALL. 
Risk Group     Features  
Percent% 
    Recommended Therapy 
Low  Hyperdiploid or trisomies 4,10,17    20   Conventional anti-metabolite-based 
therapy   T(12,21)     20 
Standard   WBC <50,000/microL    15   Intensified antimetabolite therapy 
  Age 1 to 9.9 years  
High   T cell Phenotype   15   Intensive multi-agent therapy  
  Age > 10 years     15 
  
  WBC > 50,000/micro , t(1;19)    6 
Very High    t(9;22)    3   Consider allogenic hematopoietic cell 
   transplantation in first remission   t(4;11); age <1year    4 
  Induction failures and slow 
  responders 
   2 
 
 
2.10.1. Induction therapy of ALL:  
 
Induction therapy is the initial phase of treatment, the first block for chemotherapy, lasting for 4 
to 6 weeks, and is designed to put the patient in complete remission, and restore normal bone 
marrow hematopoiesis. More than 90 percent of children and adolescents with ALL come in 
complete remission at the end of induction therapy regardless of their initial risk grouping 
(Seibel, 2008 and Stacy et al., 2015). 
 
Early clearance of lymphoblasts from the bone marrow and the presence of minimal residual 
disease at day 15 and the end of induction therapy at day 33 are the best indicators of clinical 
outcome. Patients who repay quickly to the induction regimen appear to have a more favorable 
outcome, whereas those who have a slow response or who lose induction therapy have a more 
guarded prognosis (Sutton et al., 2009).  
 
The agents used during induction phase include vincristine, corticosteroids, and asparaginase, 
with most regimens adding an anthracycline such as usually doxorubicin or daunorubicin. 
However, both anthracyclines have been shown to have similar efficacy and toxicity in 
randomized trials. Certain groups spare the addition of anthracycline to those with lower risk 
groups in an effort to decrease toxicity. The corticosteroid used is often prednisone or 
dexamethasone, with dexamethasone demonstrating improved CNS penetration and decreased 
risk of relapse, but with increased incidence of toxicities such as avascular necrosis, infection, 
and reduction in linear growth (Seibel, 2008 and Stacy et al., 2015).  
Several different agents for asparagine depletion exist as well, including polyethylene glycol 
(PEG) asparaginase and Erwinia asparaginase. PEG asparaginase has been modified by 
covalently attaching polyethylene glycol, which has been demonstrated to result in a longer half 
  
life and decreased immunogenicity in comparison with native Escherichia coli L-asparaginase. 
However, randomized trials have also shown superior efficacy of the pegylated formulation. 
Nevertheless, Erwinia asparaginase is often given to the patients who have experienced an 
allergic reaction to PEG asparaginase, and requires a more frequent administration schedule 
(Stacy et al., 2015). 
 
2.10.2. CNS preventive therapy:   
 
Leukemic involvement of the CNS at the time of diagnosis is an uncommon result, occurring in 
less than 5 percent of patients (Bleyer, 1988 and Seibel, 2008). Although bone marrow remission 
could be achieved using systemic chemotherapy, most children eventually developed CNS 
relapse in the absence of specific therapy directed toward this site. This approach includes both 
treatment of patients with clinical CNS disease at diagnosis and prophylaxis for patients with 
subclinical disease (Stacy et al., 2015). 
 
There are several methods of achieving the goal of eradication of disease from the CNS, 
including direct intrathecal administration of chemotherapy, systemic administration of 
chemotherapy able to penetrate the blood-brain barrier, and cranial radiation. All treatment plans 
include intrathecal administration of chemotherapy beginning during remission induction.   
Some protocols include intrathecal treatment throughout therapy, whereas others do not include 
it in maintenance (Seibel, 2008 and Stacy et al., 2015). 
  
There are several options for intrathecal chemotherapy include intrathecal methotrexate or a 
combination of intrathecal methotrexate, cytarabine, and hydrocortisone as triple intrathecal 
therapy. Studies have shown no significant difference in overall or event free survival between 
them, although some evidence points to decreased frequency of CNS relapse with the use of 
triple intrathecal therapy. Systemically administered chemotherapy with CNS effects includes 
dexamethasone, high dose methotrexate, 6-mercaptopurine, cytarabine or cyclophosphamide, 
and L-asparaginase (Seibel, 2008 and Stacy et al., 2015). 
 
2.10.3. Consolidation therapy of ALL: 
 
  
Consolidation or intensification therapy is the second phase of ALL treatment and is initiated 
soon after realization of complete remission. Continuing treatment is required to eradicate the 
submicroscopic residual disease because small numbers of leukemic lymphoblasts referred to as 
MRD still in the bone marrow although histologic proof of complete remission after induction 
therapy. In such cases, relapse occurs quickly if therapy is not continued (Stacy et al., 2015). 
 
The goal of post-induction chemotherapy is to prevent leukemic regrowth, reduce residual tumor 
burden, and block the evolution of drug resistance in the remaining leukemic cells (Stacy et al., 
2015). 
 
Intensification of therapeutic regimens last approximately between 6 to 9 months, and has been 
regulated depend on the patient's risk of poor outcome. A reduction of intensification therapy for 
patients with good prognosis while giving more intensive treatment for those in the high risk 
group with the goal of improving survival (Möricke et al., 2008, and Stacy et al., 2015). 
  
This phase of chemotherapy involves combinations of different chemotherapeutic agents to 
maximize synergy and minimize drug resistance, usually including agents not used in the initial 
remission induction such as mercaptopurine, thioguanine, methotrexate, cyclophosphamide, 
etoposide, and cytarabine (Stacy et al., 2015). 
 
2.10.4. Maintenance therapy of ALL:  
 
Maintenance or continuation chemotherapy phase is the third, final, and longest stage of 
treatment in pediatric ALL. A much less intensive regimen than the prior chemotherapy, and the 
prolonged maintenance phase has been demonstrated to lower the risk of relapse once remission 
has been established after fulfillment of the consolidation or intensification phase of therapy. It 
often lasts at least 2 years, and the goal is to kill any remaining leukemia cells that may regrow 
and cause a relapse (Seibel, 2008 and Stacy et al., 2015). 
The cornerstone of maintenance therapy is antimetabolite therapy with methotrexate and 
mercaptopurine, and both drugs are available in oral formulations. Some regimens also include 
monthly vincristine and steroids, although the evidence for additional benefit is unclear (Seibel, 
2008 and Stacy et al., 2015). 
  
 
2.11. Difficulties in defining complete remission in ALL 
 
The primary goal of induction therapy for ALL is achievement of an initial complete remission 
defined as the eradication of all leukemia cells (less than 5% of blasts) from the bone marrow 
and blood detectable by microscopic review and the restoration of normal hematopoiesis (more 
than 25% cellularity and normal peripheral blood counts) (Cavé et al., 1998, and Stacy et al., 
2015). Complete remission has historically been defined depend on  morphologic criteria, and it 
has been proposed that an assessment of MRD might define a more tough (complete MRD 
response) that may be better able to predict prognosis (Cavé et al., 1998, and Stacy et al., 2015).  
 
This approach is supported by several observations that explain the difficulty in ascertaining 
whether a patient with ALL in morphologic complete remission is likely to remain disease free 
(Cavé et al., 1998): 
1:Hematogones: Morphologic evaluation may be unable to differentiate between ALL blast cells 
and lymphoid precursors (hematogones) or activated mature lymphocytes. This uniqueness is 
particularly difficult in samples of bone marrow recovering from chemotherapy or 
transplantation, where hematogones may account for 10% of the lymphoid cells. 
2:Sampling error: A single bone marrow specimen represents only a very small percentage of the 
total bone marrow cellular population and thereby presents a potential for sampling error. 
However, several documented cases exist in which a bone marrow aspiration was normal at one 
site and showed leukemia at another. 
3:Detection limits: The detection of ALL blasts by morphologic review or conventional 
cytogenetics is limited by operator error and the number of metaphases evaluated. 
 
2.12. Minimal Residual Disease in ALL  
 
In the past, treatment response has been monitored by morphological examination of bone 
marrow aspirates, and due to this process has a limited sensitivity and specificity, it can result in 
failure to detect residual leukemic cells, potentially leading to under treatment and an increase 
risk of relapse. On the Contrary, misclassification of normal cells such as ALL blasts may result 
in over treatment and an increase in the risk of treatment related morbidity (Gaipa et al., 2013). 
  
Over the past 3 decades, remarkable advances have been achieved in the treatment of ALL in 
children. Although current treatment strategies result in long term remission for approximately 
80% of children with ALL, the remaining 20% ultimately relapse, and cure rate after relapse is 
about 25% to 40%. Furthermore, some subgroups of children who now receive intensive therapy 
are likely to be over-treated and may well be cured using less intensive regimens, resulting in 
reduced toxicity and fewer long term side effects (Conter et al., 2009). 
In addition to risk factors associated with the patient such as sex, and age at diagnosis and risk 
factors associated with the disease such as white blood cell count at diagnosis, and 
immunophenotyping, measurement of in vivo treatment effectiveness has confirmed to be the 
most important in predicting patient clinical outcome and risk of relapse. Many techniques have 
been developed to refine morphology in assessing response to treatment, including 
immunological or molecular markers, fluorescent in situ hybridization, in vitro drug response, 
and colony assays. This technologic advancement drove to introducing the concept of Minimal 
Residual Disease, which has challenged the conventional definition of remission (Conter et al., 
2009). 
Minimal Residual Disease is the presence of leukemic cells below the threshold of detection by 
conventional morphologic methods, and is an important component of patient evaluation and 
powerful predictor of clinical outcome over the course of sequential therapy in pediatric ALL 
(Karawajew et al., 2015). Studies in children with ALL have demonstrated the strong correlation 
between MRD and risks of relapse, as well as the prognostic significance of MRD measurements 
during and after initial induction therapy (Bruggemann and Campana, 2010). 
The most important time for MRD assessment are upon completion of initial induction, and 
additional time points may be useful depending on the regimen of treatment used. However, the 
minimal limit of assay sensitivity to confirm MRD negativity should be <0.01%, and there are 
multicolor flow cytometry and PCR methods can detect leukemic cells at a sensitivity threshold 
of <0.01% bone marrow mononuclear cells (Bruggemann and Campana, 2010). 
MRD positivity is defined by the presence of 0.01% or more ALL cells; the risk of relapse is 
generally proportional to the level of MRD, particularly when measured during or at the end of 
remission induction therapy. However, MRD is typically an independent strong prognostic factor 
that can identify poor responders among patients with acute lymphoblastic leukemia (Campana, 
2010). 
  
 
The large majority of patients with newly diagnosed ALL attain a morphologic and cytogenetic 
complete remission after induction chemotherapy. While most children experience prolonged 
relapse free survival, some children will relapse and die of leukemia. Relapse is result from 
residual leukemic cells that remain following the achievement of complete remission, but are 
below the limits of detection using conventional morphologic assessment. These subclinical 
levels of residual leukemia are MRD and can be evaluated using more sensitive assays (Coustan-
Smith et al., 2000).  
 
Complete remission was defined as the lack of physical signs of leukemia or detectable leukemia 
cells on blood smears, a bone marrow with active hematopoiesis and less than 5% leukemia blast 
cells, and normal cerebrospinal fluid (Conter et al., 2009). 
Groups collaborating in the International Berlin-Frankfurt-Munster Study Group (I-BFM-SG) 
have pioneered the evaluation of MRD at days 33 and 78 of treatment as a time point 1 and 2 
respectively to stratify patients into low, intermediate or high  risk groups (Conter et al., 2009). 
In this risk group classification, time point 1 appeared to be particularly useful for recognizing 
low, and intermediate risk patients and time point 2 for the recognition of high risk patients. 
MRD based risk group classification is used for treatment stratification in pediatric ALL 
protocols of the BFM–Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP) to 
identify the different response groups and differences in overall treatment response within T-
ALL and precursor B-ALL (Willemse et al., 2002). However, negativity of MRD at time point 1 
(day 33) was the most favorable prognostic factor (Schrappe et al., 2011). 
  
2.13. Methods for detecting minimal residual disease  
 
An assortment of techniques have been studied for the detection of residual disease, including 
cytogenetics, cell culture systems, FISH, Southern blotting, Multicolor flow cytometry, and 
Polymerase Chain Reaction (Campana, 2003 and Bacher et al., 2008). 
 
MRD assays for ALL should allow to the detection of one leukemic cell among 10,000 normal 
cells or more. They should also reliably discriminate leukemic and normal cells, and allow a 
  
timely output of the results. Finally, they should be robust enough to support consistent MRD 
estimates when applied in different laboratories. Currently, the most reliable methods to study 
MRD in ALL are flow cytometric analysis of leukemia associated immunophenotypes, and 
polymerase chain reaction amplification of antigen receptor gene rearrangements (Gaipa et al., 
2013). 
 
 
2.13.1. Multicolor Flow Cytometry:  
 
Multicolor flow cytometry uses a laser to determine specific immunophenotypic features of up to 
thousands of cells per second. MRD can be identified using flow cytometry depend on the 
irregular expression of antigens (Al-Mawali et al., 2009).  
 
Two examples explain the power of multicolor flow cytometry technique to determine MRD: 
 
1: In B-cell lineage ALL, leukemic blasts nearly always co-express CD10, CD19, CD20, CD22, 
CD34, nTdT, and CD58 in addition to some T-cell antigens including CD5 and CD7, and 
myeloid antigens including CD13 and CD33 (Campanaa and Coustan-Smitha, 2004 and 
Karawajew et al., 2015).  
2: In T-cell lineage ALL, leukemic blasts nearly always co-express terminal transferase, CD2, 
cytoplasmic CD3 (cCD3), CD5, nTdT, CD34, and CD7 (Krampera et al., 2003, and Campanaa 
and Coustan-Smith, 2004). 
 
Sequential MRD monitoring using multi-parameter flow cytometry technique has been shown to 
be a valuable predictor of relapse in pediatric ALL (Coustan-Smith et al., 1998 and Karawajew 
et al., 2015). As an example, in one study, the cumulative rate of relapse for those negative for 
MRD by flow cytometry was 10 percent, whereas it was 23, 43, and 72 percent for those with 
MRD of <0.1, 0.1 to <1.0, and ≥1.0 percent, respectively (Coustan-Smith  et al., 2000). 
 
2.13.1.1. Advantages of flow cytometry technique: 
 
Advantages of  flow cytometry technique for the detection of MRD include (Brüggemann et al., 
2010): 
  
 
1:Wide applicability: Immunophenotyping with flow cytometry technique can be applied to 80- 
95 percent of patients with ALL.  
2:Speed: Reporting of results on the same day. 
3:Quantitative: Results from flow cytometry technique are quantitative rather than qualitative, 
although not yet standardized. 
4:Gives additional information on the benign and malignant cells present in the sample, which 
may allow for drug targeting.  
5:Bone marrow and whole blood may be used as the sample source. 
 
2.13.1.2. Limitations of flow cytometry technique: 
 
Limitations of flow cytometry technique for MRD assessment include (Li et al., 2003 and 
Campanaa and Coustan-Smith, 2004): 
 
1:Hematogones: Low frequency normal hematopoietic progenitor cells (hematogones), similar to 
leukemic blasts, may express the same cytoplasmic or surface-bound marker profile, displaying 
distinction between normal and malignant cells difficult in this setting. 
2:Immunophenotypic shifts: There is also the potential for a change in immunophenotypic 
expression of the leukemic cells during disease progression, resulting in a false negative result. 
3:Low cellularity of bone marrow samples during and after induction therapy. 
 
2.13.2. Polymerase Chain Reaction: 
 
PCR can amplify a DNA or complementary DNA (cDNA) sequence unique to the leukemic 
clone resulting in the detection of one malignant cell among 10^4 to 10^5 normal cells. There are 
two types of targets used to detect MRD in ALL patients (Brüggemann et al., 2006): 
 
1: Immunoglobulin (Ig) or T-cell receptor (TCR) gene rearrangements.  
2: Leukemia-specific chromosomal rearrangements. 
 
2.13.2.1. The advantages of PCR technique for MRD monitoring:  
 
Advantages of PCR technique for MRD monitoring include (Brüggemann et al., 2006 and 2010): 
  
 
1:Extraordinary sensitivity: While the sensitivity for each junctional region target varies, the 
sensitivity of PCR is typically 0.5 to 1.0 log higher than that obtained with flow cytometry 
technique. 
2:Wide applicability: PCR testing is viable to most cases of ALL given the high frequency of Ig 
and TCR gene rearrangements in ALL. 
3:Speed: In just a few hours, PCR can amplify a single DNA molecule a million fold. 
4:Sample stability: The DNA samples tested with PCR are very stable during transport. 
5:Minimal tissue requirements. 
6:Standardized method. 
 
2.13.2.2. Limitations of PCR technique for MRD monitoring: 
 
The disadvantages of PCR for MRD monitoring enclose a variety of technical and biological 
issues including (Konrad et al., 2003 and Chen et al., 2006): 
 
1:Contamination of the reaction product, requiring tough quality control.  
2:Poor reproducibility when small numbers of transcripts are present. 
3:Evolution of the leukemic clone, sub-clone formation, and or the presence of oligo-clonal 
populations that can cause both false-negative and false-positive results. 
4:Need for diagnostic sample: Because the junctional region rearrangements are solitary to the 
leukemia clone, a sample from the time of diagnosis must be obtainable to determine the suitable  
primers. 
5:Restricted to experienced molecular hematology laboratories. 
 
2.13.3. Response defined by using MRD:  
 
In addition to standardization of the techniques used to assess and quantify MRD, it is important 
that clinicians and researchers use common terminology to report individual patient findings and 
allow for the comparison of trial outcomes. As such, a panel of representatives of the major 
European study groups on children and adult ALL has suggested the following definitions 
(Brüggemann et al., 2010):  
 
  
1:Complete MRD response: No MRD is detected with assessment that responds with a set of 
minimal technical requirements for the method used. 
2:MRD persistence: Presence of a continuously quantifiable MRD positivity measurable at least 
two time points with at least one relevant treatment element in between. 
3:MRD reappearance: Conversion from MRD negativity to quantifiable MRD positivity, ideally 
with confirmation from a second sample prior to a change in treatment. 
 
2.14. The Flow Cytometry Technique 
 
In 1934: Moldavan described a photoelectric technique for counting cells flowing through a 
capillary tube. The real beginning of modern flow cytometry started in 1965 when Fulwyler built 
a cell sorter using the Coulter principle to size cells and electrostatic charging of droplets to sort 
them. After few years by combining the measurement of volume, light scatter and fluorescence 
into a single instrument, Paul Mullaney introduced multi-parameter flow cytometry. (BD 
Biosciences., 2000). 
However, the ability to measure side scatter was added by extensive experiments carried out by 
Gary Salzman. By the mid 1970s, flow cytometers were entering the marketplace, and Leonard 
Herzenberg came up with the term, Fluorescence Activated Cell Sorter (FACS) (BD 
Biosciences., 2000). 
Immunophenotyping using flow cytometry technique has become the method of choice in 
identifying and sorting cells within complex populations. Applications of this technology have 
occurred in both basic research and clinical laboratories. Immunophenotyping is useful in our 
understanding the origin and nature of leukemia, and the regulation of hematopoietic cell 
differentiation and maturation (BD Biosciences., 2000). 
 
Fluidics, optics and electronics are the three main systems that make up a flow cytometer. The 
basic operation of a flow cytometer is that a tube containing the prepared cells under 
investigation is placed in the flow cytometer. The sample is drawn up from the sample vessel and 
pumped into the flow chamber (flow cell) through tubing. Cells flow through the flow chamber 
one at a time very quickly and are presented to one or more light sources (Lasers). The laser 
beam hits the cells as they pass through the flow chamber. The way the light bounces off each 
cell gives information about the cells physical characteristics. Light scatter and or fluorescence if 
  
fluorescent molecules are present on the particle are captured depending on the type of 
fluorochromes, spectrally filtered and directed to appropriate photodetectors for conversion to 
electrical signals (BD Biosciences., 2000). 
 
Light scatter is collected at two angles: Forward Scatter (FSC) and side scatter (SSC). Forward 
scatter measures scattered light in the direction of the laser path and measures the size of the cell. 
Side scatter measures scattered light at 90 degrees to the laser path and measures the granularity 
of the cell. 
 
The electronics in the cytometer amplify and process the resulting data. They convert analogue 
data to digital data which is stored in the computer. This data can be analyzed to provide 
information about subpopulations within the sample (Figure 2.6) (BD Biosciences., 2000). 
 
Figure 2.6: Scattered and emitted light signals are converted to electronic pulses that can be 
processed by the computer.  
 
 
 
 
 
 
 
 
  
Chapter three  
Methodology 
 
3.1. Study design 
 
This study is an incident study, was conducted in January 2015 based on clinical selection of 
pediatric ALL due to high incidence of ALL cases in comparison with other leukemia among 
children. However, the diagnosis of pediatric ALL was based on signs and symptoms, and 
clinical laboratory results. The immunophenotyping analysis was done by flow cytometry 
technique that used in routine clinical laboratories for the diagnosis, prognosis and monitoring of 
ALL. 
Pediatric ALL cases were selected from those admitted to Huda Al-Masri pediatric cancer 
department at Beit-Jala hospital in Bethlehem, this hospital is one of the largest centers of 
pediatric oncology and hematology centers in Palestine. 
 
3.2. Target population 
 
The target population of this study were Palestinian children with ALL, age between 0-14 
years, diagnosed and treated at Huda Al-Masri pediatric cancer department at Beit-Jala hospital 
in Bethlehem, and west bank area residents through the study period. 
 
3.3. Sampling 
 
According to the previously mentioned aims of this incident study, we had selected pediatric 
ALL cases from January 2015 to December 2015. A total of 15 consecutive children (7 females, 
8 males) < than14 years with newly diagnosed ALL were diagnosed by pediatric oncologists at 
Huda Al-Masri pediatric cancer department at Beit-Jala hospital. 
 
 
 
3.4. Inclusion Criteria 
  
Pediatric ALL patients residents of west bank area of Palestine, < than14 years old, and admitted 
to Huda Al-Masri pediatric cancer department at Beit-Jala hospital from January 2015 to 
December 2015. 
 
3.5. Exclusion Criteria 
Pediatric ALL patients not a resident of west bank area of Palestine, older than 14 years old, any 
patient without flow cytometric analysis or transferred outward to another pediatric oncology 
center. 
3.6. Definition of study area 
 
This study was conducted in a single cancer center in southern west bank area of Palestine, 
which includes patients from west bank area according to the appendix 1, except in Jerusalem 
governorate. 
3.7. Data collection tools 
 
Multiple sources of data were used during this study to achieve a comprehensive idea about the 
immunophenotyping of pediatric ALL. 
3.7.1. Medical files: Data of pediatric ALL patients in their medical files were reviewed with 
ethical consideration of patient privacy to obtain some clinical features of the given patient at 
Huda Al-Masri pediatric cancer department at Beit-Jala hospital in Bethlehem. 
  
3.7.2. Flow Cytometer: All cases either retrospective or incident were tested by College of 
American Pathologists (CAP) accreditation pathology department at King Hussein Cancer 
Center (KHCC) in Amman-Jordan on bone marrow aspirate samples collected in 
Ethylenediaminetetraacetic acid (EDTA) tubes according to a two step strategy using panels of 
monoclonal antibodies based on European Group for Immunological Characterization of 
Leukemia (EGIL). For the study purpose, the immunophenotyping of the incident target cases at 
2015 was performed at Huda Al-Masri pediatric cancer department at Beit-Jala hospital in 
Bethlehem on bone marrow aspirate samples collected in Ethylenediaminetetraacetic acid 
(EDTA) tubes according to a two step strategy, and for validation purpose, the achieved results 
were compared with the KHCC results of the same cases and no significant difference was noted. 
  
 
At Huda Al-Masri pediatric cancer department at Beit-Jala hospital in Bethlehem, the reactivity 
of fluorescent conjugated monoclonal antibodies directed against lymphoid and myeloid 
associated antigens was evaluated on the surface of leukemic cells. The intracytoplasmic Ig, 
CD3, CD79a and MPO antigens as well as nTdT staining were evaluated by fluorescent 
conjugated monoclonal antibodies after fixation and permeabilization of leukemic cell. Stained 
cells were analyzed by flow cytometry technique on a multicolor BD FACS-Callibur flow 
cytometer (Becton Dickinson Calibrate). 
Minimal Residual Disease results were evaluated by examining the most common antigens or 
CD markers through reactivity of fluorescent conjugated monoclonal antibodies directed against 
lymphoid associated antigens for each ALL type on the surface of bone marrow cells after the 
induction point 1 at day 33 of treatment by flow cytometry technique on a multicolor BD FACS-
Callibur flow cytometer. 
Immunological Staining: A volume of 100 ul of each sample of bone marrow aspirate was mixed 
with 3 ml of 1X Red Blood Cell lysing buffer solution-eBioscience in each falcon tube, followed 
by vortex by Turbo mixer –LW Scientific for few seconds, then incubation in the refrigerator 
without light for 20 to 30 minutes. Each falcon tube was centrifuged by Eppendorf centrifuge-
5702 at speed 3000 round per minute for 3 minutes.  
The supernatant was removed and put it again on vortex for few seconds. A volume of 3 ml of 
0.01M Phosphate buffer saline-eBioscience was added in each falcon tube for washing, then the 
centrifugation was repeated for 3 minutes at speed 3000 round per minute, and also the 
supernatant was removed from each falcon tube.  
A volume of 10 ul of each antibody (5ul/0.5ug, eBioscience), was added in each falcon tube as in 
Table 3.1, followed by vortex for few seconds, and then centrifugation for 15 minutes in the 
refrigerator without light. Then again, a volume of 3 ml of phosphate buffer saline was added 
followed by centrifugation for 3 minutes at speed 3000 round per minute, and the supernatant 
was removed from each falcon tube. Finally, 0.5 ml of phosphate buffer saline was added to each 
falcon tube and the samples were ready for reading.  
For intracellular staining: before adding 0.5 ml of phosphate buffer saline for each falcon tube, 
100 ul of 1C Dako solution-eBioscience for fixation was added followed by vortex for few 
  
seconds, and incubation for 10 minutes in the refrigerator without light. A volume of 3 ml of 
phosphate buffer saline was added in each falcon tube followed by centrifugation for 3 minutes 
at speed 3000 round per minute, and removing the supernatant.  
Then, a volume of 100 ul of 10X permeabilization buffer-eBioscience was added in each falcon 
tube followed by vortex for few seconds, and then immediately a volume of 5 ul of each 
antibody was added in falcon tubes followed by vortex for few seconds and incubation for 15 
minutes in the refrigerator without light.  
Moreover, a volume of 3 ml phosphate buffer saline was added in each falcon tube followed by 
centrifugation for 3 minutes at speed 3000 round per minute and removing the supernatant. 
Finally, a volume of 0.5 ml phosphate buffer saline was added to each falcon tube to become 
ready for reading. 
However, the antibodies used in this study were panels of mouse monoclonal antibodies in Acute 
Leukemia Immunophenotyping kit (Becton Dickinson) (Table 3.1). There are Anti CD10, Anti 
CD19, Anti CD20, Anti CD1a, Anti CD2, Anti CD8, Anti CD4, Anti CD5, Anti CD3, Anti 
CD22, Anti CD7, Anti CD33, Anti CD38, Anti CD117, Anti HLA-DR, Anti CD13, Anti CD34, 
Anti CD61, Anti CD14, Anti CD11b, Anti cytoplasmic CD79a (cCD79a), Anti nTdT, Anti 
cMPO, Anti Light chains (Kappa or Lambda), Anti surface Ig, Anti cCD3, and Anti CD45. 
 
 
 
 
 
Table 3.1: Multicolor parameters of antibodies to CD markers in acute lymphoblastic leukemia 
profile.  
Tube Number  First Color (FITC) Second Color (PE) Third Color (Per CP) Fourth Color (APC) 
1 (control)           ____           ____  CD45         ____ 
  
2 CD10 CD19 CD45 CD20 
3 CD1a CD2 CD45 CD3 
4 CD4 CD5 CD45 CD7 
5 cCD3 cCD79a CD45 cMPO 
6 CD22 CD34 CD45 CD38 
7 CD13 CD14 CD45 CD33 
8 CD61 CD71 CD45 CD117 
 
9 CD8 CD11b CD45 HLA-DR 
10 nTdT sIg CD45 Light chains 
 
 
Leukemic samples were considered positive for a particular antigen if 20% or more leukemic 
cells reacted with a particular antibody for lymphoid markers (CD1a, CD2, CD3, cCD3, CD4, 
CD5, CD7, CD8, CD10, CD19, CD20, CD22, CD34,  CD38, CD45, cCD79a, HLA-DR, nTdT, 
sIg, Kappa or Lambda light chains) and 30% or more for myeloid markers (CD11b, CD13, 
CD14, CD33, CD34, CD45, CD61, CD71, CD117, cMPO) (Chiaretti et al., 2014). 
 
In the following 2 representative examples in Figures 3.1 and 3.2, the results of flow cytometry 
analysis for acute lymphoblastic leukemia patients with different type of ALL depending on 
immunophenotyping are illustrated. 
 
 
Positive CD19 and negative CD33                                       Positive CD10 and negative CD3 
  
                                  
 
 Positive TdT and CD79a                                               
Positive HLA-DR and negative CD34 
      
 
Negative CD20 and CD33                                           Positive CD22 and negative CD33  
 
 
Figure 3.1: Results of flow cytometry analysis for acute lymphoblastic leukemia patient with 
precursor B-cell immunophenotype. 
Positive CD2 and negative HLA-DR                                                        Negative CD3 and CD16 
  
      
    Positive CD4 and CD8                                                             Positive CD7 and negative CD56
 
                                   
                                                      Positive CD5 and negative CD20 
 
Figure 3.2: Results of flow cytometry analysis for acute lymphoblastic leukemia patient with T-
cell immunophenotype. 
 
3.8. Data analysis programs 
 
  
Statistical analysis of the results was performed using Statistical Package for the Social Sciences 
(SPSS) version 23.0 (IBM, Corporation) and Microsoft Excel version 2016, showing the 
immunophenotype of pediatric ALL patients in Palestine, and clinical features of 
them. Categorical variables and results that presented as frequencies and percentages with p-
values were analyzed by using Pearson Chi Square, and Fisher’s Exact test. The continuous 
variables as mean and median were presented and analyzed using Independent Sample T-Test. 
 
3.9. Ethical Consideration 
 
Ethical approval for this study was approved by AL-Quds University (AQU) local Helsinki 
ethical committee for medical research. This committee follows the moral aspect and high 
privacy in dealing with the data contained in this study, where it is encoded these data and 
tabulated without mentioning to the participants. A written consent was taken from all patients or 
their families. This study also was approved, and permission for the research was given by 
Palestinian Ministry Of Health (MOH) and administration of Huda Al-Masri pediatric cancer 
department at Beit-Jala hospital in Bethlehem, Palestine. 
 
 
 
 
 
 
 
 
 
Chapter four  
 
  
Results 
4.1. Age distribution of the different ALL subtypes 
The age distribution of the precursor B-cell ALL subtype in Figure 4.1, shows that precursor B-
cell ALL patients were younger with peak incidence between 2 and 5 years. 
 
 
Figure 4.1: Age distribution of 14 children with precursor B-cell acute lymphoblastic leukemia.  
 
4.2. Geographical distribution of ALL subtypes 
Geographical distribution of Palestinian pediatric ALL in a single cancer center experience as in 
Table 4.1, shows that about half of the cases (46.7%) were from Hebron governorate, includes 
50% of precursor B-cell ALL cases and 0% of T-cell ALL cases. We also found that 13.3% of 
ALL cases occurred in Bethlehem governorate with 7.1% of precursor B-cell ALL cases and 
100% of T-cell ALL cases, because there was just one case of T-cell ALL. For normalization of 
the geographical distribution results, the number of inhabitants in Hebron governorate is about 3 
times more than the number of inhabitants in Bethlehem governorate, and the number of cases in 
Hebron governorate was about 3 times more than number of cases in Bethlehem governorate as 
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in Table 4.1. For this reason, the percentage of cases that diagnosed in Hebron governorate was 
similar to the percentage of cases that diagnosed in Bethlehem governorate.  
In Ramallah governorate, there was 20% of ALL cases with 21.4% of precursor B-cell ALL and 
0% of T-cell ALL. Each of Nablus, Jenin and Tulkarm governorates contain 6.7% of ALL cases 
with 7.1% of precursor B-cell ALL cases and 0% of T-cell ALL cases (Table 4.1). The number 
of ALL cases in Ramallah, Nablus, Jenin, and Tulkarm don’t reflect the total number of cases in 
these governorates.  
However, the results of geographical distribution of pediatric ALL cases were not statistically 
significant between ALL subtypes in each governorate. 
 
Table 4.1: Geographical distribution of pediatric ALL subtypes at a single cancer center 
experience in southern west bank area of Palestine. 
 
All Patients 
(n=15 
T-cell ALL 
(n=1) 
Precursor B-cell 
ALL (n=14) 
Number of 
Inhabitants 
P-
value 
Governorates >0.05 
Hebron 7 (46.7%)  0 (0%) 7 (50%) 706,508  
Bethlehem 2 (13.3%)     1 (100%) 1 (7.1%) 216,114  
Nablus 1 (6.7%)  0 (0%) 1 (7.1%) 380,961  
Ramallah 3 (20%) 0 (0%) 3 (21.4%) 348,110  
Jenin 1 (6.7%) 0 (0%) 1 (7.1%) 311,231  
Tulkarm 1 (6.7%) 0 (0%) 1 (7.1%) 182,053  
 
 
 
4.3. Distribution of ALL cases according to immunophenotypes 
The study group comprised 15 acute lymphoblastic leukemia cases (<14 years). There were 7 
females and 8 males with a male/female ratio of 1.14:1. Immunophenotyping analysis showed 
  
that the precursor B-cell phenotype was encountered in 14 (93.3%) cases, mature B-cell 
phenotype in Zero (0%) cases, and T-cell phenotype in 1 (6.7%) case (Table 4.2). 
4.3.1. ALL characteristics depending on the distribution of immunological subtypes: 
The patients characteristics are summarized in Table 4.2. The immunophenotypic distribution of  
ALL subtypes is not clearly influenced by clinical features. Compared with precursor B-cell 
ALL, Age at diagnosis (P >.05), Gender (P >.05), higher or lower leukocyte count at diagnosis 
(P >.05), and Positive CNS disease (P >.05), Mediastinal mass (P >.05), and the same relation 
with T-cell ALL subtype.  
4.3.2. Negative MRD at the end of induction point 1 (day 33): 
We examined negative MRD at the end of induction point 1 at day 33 after treatment when the 
reactivity of fluorescent conjugated monoclonal antibodies directed against lymphoid associated 
antigens for each ALL type on the surface of bone marrow cells is less than 0.01% of total cells 
expressing the most common CD markers for each ALL type, to test if complete remission will 
occurs in most of cases as in developed countries. We found that 13 of pediatric ALL cases 
(86.7%) were subjected to complete remission after the end of induction point 1 at day 33 with 
the only T-cell ALL case and 12 cases that constituted 85.7% of precursor B-cell ALL cases.  
Two cases (14.3%) from precursor B-cell ALL cases were with positive MRD because more 
than 0.01% of total cells expressing the most common CD markers, one case with 0.85 and the 
second case with 0.5 of total cells were blasts expressing the most common CD markers for 
precursor B-cell type (CD19, CD10, CD34). However, the results of negative or positive MRD 
were not statistically significant (Table 4.2). 
4.3.3. CNS leukemia at diagnosis of ALL 
We examined the presence of extramedullary disease such as in central nervous system because 
it is a factor used to determine the intensity of treatment. We found that just 1 case (7.1%) of 
precursor B-cell ALL cases had positive CNS disease. 
Table 4.2: Characteristics of acute lymphoblastic leukemia patients. 
Features 
All Patients 
(n=15) 
T-cell ALL 
(n=1) 6.7% 
Precursor B-cell 
ALL (n=14) 
P-value 
  
93.3% 
Age of Diagnosis (Year) >0.05 
Mean 5.1 ------ 5.3  
Median 5 ------ 4.5  
Range 2 - 12 ------ 2 - 12  
< 1 0 (0%) 0 (0%) 0 (0%)  
1 - 9 14 (93.3%) 1 (100%) 13 (92.9%)  
10+ 1 (6.7%) 0 (0%) 1 (7.1%)  
Gender >0.05 
Male 8 (53.3%) 0 (0%) 8 (57.1%)  
Female 7 (46.7%) 1 (100%) 6 (42.9%)  
M/F ratio 1.14 : 1 0 1.33 : 1  
Leukocyte Count (K/ml) at Diagnosis  >0.05 
Mean 35 ------ 37.3  
Median 18.7 ------ 25.4  
Range 1.4 - 105 ------ 1.4 - 105  
<50 9 (60%) 1 (100%) 8 (57.1%)  
≥50 6 (40%) 0 (0%) 6 (42.9%)  
Positive CNS Disease 1 (6.7%) 0 (0%) 1 (7.1%) >0.05 
Positive Mediastinal mass 1 (6.7%) 1 (100%) 0 (0%) >0.05 
MRD Results  >0.05 
Negative MRD <0.01 of 
cells at end of induction 
point 1 (day33) 13 (86.7%) 1 (100%) 12 (85.7%) 
 
Positive MRD >0.01% of 
cells at end of induction 
point 1 (day33) 2 (13.3) 0 (0%) 2 (14.3%) 
 
4.4. Imunophenotype of ALL cases 
ALL cell lineage divided into two subtypes: B-cell lineage ALL and T-cell lineage ALL. There 
were 15 children (7 females and 8 males) with ages ranging from 2 to 12 years and median age 
of 5 years (Table 4.2). 
  
4.4.1. Precursor B-Cell immunophenotype: 
Fourteen children with precursor B-cell phenotype were studied. There were 6 females and 8 
males (male/female ratio of 1.33:1) with ages ranging from 2 to 12 years and median age of 4.5 
years (Table 4.2).  
Based on the reactivity of precursor B-cell ALL cells with various anti-precursor B-cell 
monoclonal antibodies (Table 4.3), all tested precursor B-Cell ALL cases expressed CD19. 
Many Cases had cCD79a, CD10, nTdT, HLA-DR in 85.7%, 92.9%, 85.7%, 92.9% respectively, 
and cells in more than 78% of cases expressed CD34. According to CD38, CD58 and  CD20 
were also found in 71.4%, 71.4% and 35.7% of cases respectively. Furthermore, myeloid 
antigens CD13 and/or CD33 occurred just in (14.2%) of cases, and CD22 was also found in few 
cases (7.1%).  
4.4.2. T-Cell immunophenotype: 
One child with T-cell ALL type was studied. Based on the reactivity of T-cell ALL cells with 
various anti-T-cell monoclonal antibodies (Table 4.3), the T-cell case cells expressed the most 
common CD markers for T-cell ALL type, and they were surface CD7, CD10, CD5, CD34, 
nTdT, and cCD3 antigens. 
 
4.4.3. Lineage heterogeneity between ALL immunophenotypes: 
Lineage heterogeneity was found only in precursor B-cell ALL cases having one or two myeloid 
associated antigens (CD13,CD33) expressed on their blast cells. Lineage heterogeneity for both 
antigens was found in 7.1% of precursor B-cell ALL cases (n=1). However, CD13 antigen was 
found in 7.1% of cases (n=1), and CD33 antigen was found in 14.2% of cases (n=2) (Table 4.3). 
Table 4.3: Immunophenotyping profiles of 15 acute lymphoblastic leukemia patients. 
Markers T-cell ALL (n= 1 ) Precursor B-cell ALL (n= 14 ) 
CD1a+ 0/1 (0%) __ 
sCD3+ 0/1 (0%) 0/14 (0%) 
cCD3+ 1/1 (100%) 0/14 (0%) 
CD4+ 0/1 (0%) __ 
  
CD5+ 1/1 (100%) __ 
CD7+ 1/1 (100%) 0/14 (0%) 
CD8+ 0/1 (0%) __ 
CD10+ 1/1 (100%) 13/14 (92.9%) 
cCD79a+ 0/1 (0%) 12/14 (85.7%) 
CD19+ 0/1 (0%) 14/14 (100%) 
CD20+ 0/1 (0%) 5/14 (35.7%) 
CD22+ 0/1 (0%) 1/14 (7.1%) 
nTdT 1/1 (100%) 12/14 (85.7%) 
CD34+ 1/1 (100%) 11/14 (78.6%) 
HLA-DR+ 0/1 (0%) 13/14 (92.9%) 
CD38+ 0/1 (0%) 10/14 (71.4%) 
CD58+ 0/1 (0%) 10/14 (71.4%) 
CD13+ 0/1 (0%) 1/14 (7.1%) 
CD33+ 0/1 (0%) 2/14 (14.2%) 
CD13+, CD33+ 0/1 (0%) 1/14 (7.1%) 
CD13-, CD33+ 0/1 (0%) 2/14 (14.2%) 
CD13+, CD33- 0/1 (0%) 0/14 (0%) 
CD13-, CD33- 0/1 (0%) 12/14 (85.7%) 
CD13+, and/or CD33+ 0/1 (0%) 2/14 (14.2%) 
 
 
 
4.5. CD10 Expression 
The correlation of CD10 positivity with age, leukocyte count at diagnosis, and gender was 
analyzed (Table 4.4). CD10 expression was found in 13 cases (92.9%) of precursor B-ALL cells 
and 1 cases (100%) of the T-ALL cells.  
CD10 expression in precursor B-ALL was not significantly frequent in patients with age range of 
1-9 years, and not significant frequent with initial low leukocyte count. In contrast, children with 
  
precursor B-ALL CD10- phenotypes were not significantly more frequently > 10 or < than 1 
year, and not statistically significant with initial high leukocyte count. 
CD10 positivity was less common in T-cell lineage and was not statistically significant 
associated with initial higher leukocyte count, and more frequently from 1 to > 10 years. 
Furthermore, children with T-cell ALL CD10- phenotypes were not statistically significant 
associated with more frequently between 1-9 years, and initial low leukocyte count. 
Table 4.4: Biological features according to CD10 expression in pediatric ALL. 
Feature 
  Precursor B-cell ALL (n=14) T-cell ALL (n=1) 
 Total of 
Patients CD10 - CD10 + P-Value CD10 - CD10 + P-Value 
 Gender   0.201   1 
 
F 7 (53.3%) 0 (0%) 
6 
(100%)   0 (0%) 
1 
(100%)   
 
M 8 (46.7%) 
1 
(12.5%) 7 (87.5)   0 (0%) 0 (0%)   
 Leukocyte Count 
(K/ml)   0.212     0.123 
 
<50 9 (60%) 
1 
(12.5%) 
7 
(87.5%)   0 (0%) 
1 
(100%)   
 
≥50 6 (40%) 0 (0%) 
6 
(100%)   0 (0%) 0 (0%)   
 
Age (Y)   
0.201 
  1 
 < 1 0 (0%) 0 (0%) 0 (0%) 
 
0 (0%) 0 (0%)   
 1 - 9 
14 (93.3%) 
1 
(7.7%) 
12 
(92.3%)   0 (0%) 
1 
(100%)   
 >10 
1 (6.7%) 0 (0%) 
1 
(100%)   0 (0%) 0 (0%)   
  
 
Chapter five  
 
Discussion 
The present work is the first and a unique study takes place in Palestine that discussing the 
immunophenotyping of pediatric ALL. It’s studying small series of acute lymphoblastic 
leukemia cases, providing an idea about the immunophenotype, some clinical features, CD10 
  
expression, age distribution, and geographic distribution of ALL subtypes in a single cancer 
center in southern west bank. We reported the results of 15 patients. 
This study is a first step towards a better understanding of ALL, as the most common pediatric 
malignancy in developed countries and in Palestine as well. 
5.1. Age and gender distribution of the ALL subtypes 
The peak age range of 2 to 5 years for precursor B-cell phenotype was similar to the pediatric 
ALL reported in developed countries (Kebriaei et al., 2003 and de Sousaa et al., 2015), and with 
male to female ratio (1.14:1) that may be similar to that reported in developed countries (Bachir 
et al., 2009), but not statistically significant. 
5.2. Geographical distribution of ALL 
According to the geographical distribution of pediatric ALL in Palestine that is largely unknown. 
The present study gives us a small idea about the geographical distribution of pediatric ALL in 
different governorates in a single cancer center experience in the southern west bank area of 
Palestine. We found that about a half of the cases (46.7%) were from Hebron governorate, 
although the percentage of cases in Hebron governorate was similar to the percentage of cases in 
Bethlehem governorate when we did the normalization for the results according to the number of 
inhabitants in both Hebron and Bethlehem governorates, so this high  number of cases in Hebron 
governorate due to the huge number of population there, and the results were not statistically 
significant. However, the cases from Ramallah, Nablus, Jenin, and Tulkarm governorates are not 
reflected the total number of patients because they are treated in other cancer centers. 
 
5.3. Immunophenotypic distribution of ALL subtypes 
In this study, the advantage is to select the best strategy for acute lymphoblastic leukemia 
diagnosis and management. Immunophenotyping was used in order to analyze 15 children with 
acute lymphoblastic leukemia. The relative frequencies of immunological subtypes in this study 
(93.3% for precursor B-cell phenotype and 6.7% for T-cell phenotype) are similar to that 
reported by the developed countries of Europe and USA (Neelkamal et al., 2013, and Hunger and 
Mullighan, 2015). 
  
5.3.1. ALL characteristics depending on the distribution of immunological subtypes: 
The clinical features of pediatric ALL in Palestine are largely unknown. This study gives us an 
idea about some clinical features of pediatric ALL in Palestine that help in determining the 
preferred protocol for the management of ALL. However, the immunophenotypic distribution of 
ALL subtypes was not clearly influenced by clinical features. May be due to we had a not huge 
sample size. 
MRD examination is a key tool towards the development of personalized treatment for children 
with ALL and flow cytometry technique has significantly contributed to expand the applicability 
of this valuable test (Gaipa et al., 2013). 
Negative MRD at the end of induction point 1 at day 33 to determine the complete remission was 
86.7% of pediatric ALL cases, so this high percentage means that the response to treatment was 
very good as in developed countries (Schrappe et al., 2011). 
Although CNS leukemia is more common in T-cell ALL than precursor B-cell ALL, and it 
occurs in fewer than 5% of children at diagnosis (Friedmann and Weinstein, 2000 and Hunger 
and Mullighan, 2015), we found that just one case with positive CNS disease was from precursor 
B-cell ALL. 
 
5.4. Cell Lineage of ALL cases 
Data concerning the antigen expression for each class of ALL showed to some extent as has been 
reported in pediatric ALL in various developing countries: 
Every case of B cell lineage ALL expressed just CD19 as reported in previous studies, and not 
all cases expressed cCD79a and CD22 as in developed countries, due to most of cases (85.7%) 
expressed cCD79a and few cases (7.1%) expressed CD22 (Campana and Coustan-Smith, 2002 
and Kaleem et al., 2003). 
Furthermore, HLA-DR, CD20, CD34 and nTdT were the most sensitive antigens for the 
precursor B-cell ALL as previous reported studies (Bachir et al., 2009, and Kaleem et al., 2003). 
  
As previous reported by the developed countries, cCD3, CD5, and CD7 were the most sensitive 
antigens for the T-cell lineage ALL (Campana and Coustan-Smith, 2002 and Kaleem et al., 
2003).  
5.5. Lineage Heterogeneity 
Aberrant expression of myeloid antigens on acute lymphoblastic leukemia cells is a well-
documented phenomenon and has no prognostic or therapeutic implications (Putti et al., 1998), 
but can be used for monitoring MRD (Campana and Pui, 1995). However, the myeloid 
associated antigens CD13/CD33 used in the current study are the most commonly antigens 
expressed in pediatric ALL cases.  
In this study, myeloid antigens expression occurred only in precursor B-cell ALL cases in 14.2% 
(n=2), that differ from developed countries due to myeloid antigens occurred in both ALL 
subtypes, although this frequency of myeloid antigens in precursor B-cell ALL between 6 to 
35% as in developed countries (Putti et al., 1998 and Pui et al., 1991). 
5.6. CD10 Expression  
CD10 expression was detected in 13 cases (92.9%) of the 14 precursor B-cell ALL cases and in 1 
T-cell ALL case (100%), due to just this case tested for this antigen. Cases of precursor B-cell 
ALL having the CD10 had low leukocyte count at diagnosis, but not statistically significant, and 
also not statistically significant that the majority of cases (92.3%) were between 1-9 years of age. 
CD10 positive T-cell ALL case was characterized by lower leukocyte count at diagnosis, and 
between 1-9 years of age, but without statistically significant. 
Studies of the prognostic significance of the CD10 expression in ALL have showed that CD10 
expression in pediatric B lineage ALL is associated with several favorable presenting features 
but is not an independent prognostic factor (Pui and Evans, 1998 and Hann et al., 1998). In T-
cell lineage, the expression of CD10 was independently associated with favorable clinical 
outcome (Pui et al., 1990 and 1993).  
However, for the larger subgroup of patients with T-lieange ALL, CD10 expression has no 
independent prognostic significance (Consolini et al., 1998). 
5.7. Conclusion 
  
This study is a unique study providing a clear idea about the immunophenotyping of pediatric 
ALL cases at a single cancer center experience in southern west bank area in Palestine, and this 
immunophenotypic distribution was similar to the general immunophenotypic distribution 
pattern in developed countries. The age distribution showed a peak incidence between 2 and 5 
years among the precursor B-cell ALL subtype as in developed countries. Geographical 
distribution of Palestinian pediatric ALL showed that about half of the cases (46.7%) from 
Hebron governorate, but with the same percentage of cases diagnosed in Bethlehem governorate 
depending on the number of inhabitants. 
The response to treatment for ALL patients was very good as in developed countries, due to the 
Negative MRD at the end of induction point 1 at day 33 was 86.7% of ALL patients. 
This effort aims to confirm the excellent significance of the immunophenotyping method for 
diagnosis and classification of pediatric ALL at a single cancer center in southern west bank in 
Palestine, to determine the prognosis and then the preferred protocol for the treatment of 
pediatric ALL to obtain better quality of life for children with cancer that is similar to the 
successful efforts of the developed countries. 
5.8. Study limitation 
1:The major limitation of this study was that the sample size is limited due to the late 
establishment of the pediatric oncology center and the results just for small number of cases for 
the study period (one year), thus the T-cell phenotypes weren’t huge which affects the 
generalization of the results.  
2:This study did not include all centers in the west bank, only one of the largest pediatric centers 
for leukemia patients in Palestine, due to lack of access to other cancer centers in Palestine and 
limited resources. 
Despite of these limitations, this study demonstrates the urgent need of investigators cooperation 
in the west bank of Palestine to create a functional cooperative group. 
 
5.9. Recommendations  
This study could carry important recommendations for pediatric oncologists and pediatric 
patients as well. It highlights the importance and the prognostic value of flow cytometry 
  
technique as a routine procedure for all pediatric ALL cases in the process of ALL diagnosis, 
prognosis, and management.  
This study also could be directed to policy makers in Palestinian MOH to make the flow 
cytometry technique a routine procedure for pediatric ALL diagnosis and management protocol, 
and could be a cornerstone for further researchers about pediatric ALL in Palestine. 
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Appendix 1: Definition of the  study area. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Appendix 2: Definition of the Estimated Population in West Bank by Region, 2015. 
 
Region Population  
West Bank  2,862,485 
Jenin  311,231 
Tubas  64,719 
Tulkarm  182,053 
Nablus  380,961 
Qalqilia 110,800 
Salfit 70,727 
Ramallah & Al-Bireh 348,110 
Jericho & Al Aghwar 52,154 
Jerusalem 419,108 
Bethlehem 216,114 
Hebron 706,508 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Appendix 3: An Arabic official letter from Al-Quds University to Beit-Jala  Hospital to 
conduct the study. 
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من  النمط الظاهري المناعي لحالات سرطان الدم الليمفاوي الحاد لدى الأطفال الفلسطينيين
 الضفة الغربية باستخدام جهاز التدفق الخلوي جنوب في خلال تجربة مركز سرطان واحد
  
 اسامة نبيل غطاس سلامة إعداد:
 إشراف: الدكتور غسان بعلوشة
 
 الملخص
الى  57سرطان الدم الليمفاوي الحاد هو أكثر انواع السرطان شيوعا لدى الأطفال, يشكل حوالي  مقدمة :ال
من  888.880لكل  4الى   3 ابة عالميا حوالي. تشكل نسبة الاصالحاد من حالات مرض السرطان %80
. و تعتبر الأبحاث المنشورة في هذا الموضوع محدودة جدا في فلسطين. و سنة 10عند عمر أقل من  السكان
من هنا قدمت هذه الدراسة نتائج واضحة و مهمة حول النمط الظاهري المناعي لمرضى سرطان الدم الليمفاوي 
 الضفة الغربية في فلسطين. أهم مركز سرطان للأطفال في جنوب الحاد عند الأطفال في
, مع الفلسطينيين فاوي الحاد عند الأطفالمتهدف هذه الدراسة الى تحديد أنماط سرطان الدم اللي  الاهداف :
, و عدد خلايا الدم البيضاء بالنسبة للعمر و النمط الظاهري المناعي السريرية مثل المظاهر توضيح أهمية
النقطة  الحد الأدنى من خلايا المرض المتبقية عندالاستجابة للعلاج بعد المرحلة التعريفية باستخدام يد تحد
  يوم من العلاج. 33الزمنية الأولى بعد 
حتى ديسمبر  1085ن يناير , و أجريت هذه الدراسة ممستحدثة دراسة لقد استخدمتالطرق: و الأدوات
في مركز هدى المصري لسرطان الأطفال في الليمفاوي الحاد مرضى أطفال سرطان الدم على   1085
الذي يقع في المنطقة الجنوبية من الضفة الغربية. و تتكون عينات البحث لدينا من حالات  مستشفى بيت جالا
عاما بسرطان الدم  40ذكور) تقل أعمارهم عن  0اناث,  7( طفل على التوالي 10ُشخصت حديثا بمجموع 
 . هذا المستشفى هو1085ورام الأطفال في مستشفى بيت جالا لأ هدى المصري  في مركز الليمفاوي الحاد
 لحالات سرطان الدم في فلسطين. اكز الأطفالمر  من أكبر واحد
  
لقد تم استعراض البيانات لمرضى أطفال سرطان الدم الليمفاوي الحاد في ملفاتهم الطبية مع أخذ الاعتبارات 
. لقد تم تنفيذ فحص النمط الظاهري بعض المظاهر السريريةللحصول على  الأخلاقية لخصوصية المرضى 
  ATDEالتي تم جمعها بإستخدام أنابيب  على عينات نخاع العظم السابقة أو الحديثة المرضى لكلالمناعي 
ري وفقا لإستيراجية إستخدام الأجسام المضادة بخطوتين بناًء على المجموعة اُلاوروبية لتوصيف النمط الظاه
الأردن الحاصل  في مركز الحسين للسرطان في عمان, دم من خلال تقنية التدفق الخلوي المناعي لسرطان ال
فحصنا النمط الظاهري للحالات لقد لغرض الدراسة,  و كلية أطباء الباثولوجي الأمريكية.على إعتماد من 
على عينات نخاع العظم جالا في مركز هدى المصري لسرطان الأطفال في مستشفى بيت  1085الجديدة في 
باستخدام جهاز  وفقا لإستيراجية إستخدام الأجسام المضادة بخطوتين ATDEالتي تم جمعها بإستخدام أنابيب 
و لقد تم توثيق النتائج من خلال فحصها مرة أخرى في مركز الحسين للسرطان بعمان و لم  .التدفق الخلوي 
 يسجل فرق يذكر بينهما.
من خلايا المرض المتبقية عن طريق فحص المواد المضادة الشائعة خلال  ئج الحد الأدنىلقد تم تقييم نتا
فعالية الأجسام المضادة المشعة مباشرة مع هذه الأجسام المضادة على سطح خلايا سرطان الدم لكل نوع من 
 التدفق الخلوي. تقنيةم يوم من العلاج باستخدا 33سرطان الدم الليمفاوي الحاد عند النقطة الزمنية الأولى بعد 
حالة سرطان دم ليمفاوي  10لقد تم إجراء التحليل الإحصائي للنتائج لمجموع عينات البحث و هي النتائج: 
من الذكور حالات  0من الإناث و حالات  7 سنة. كان هناك  40 منحاد تم تشخيصها حديثا بعمر أقل 
ري لمختلف أنواع سرطان الدم الليمفاوي الحاد بأن أظهر التوزيع العم من الذكور للإناث. 1.141:بنسبة 
بة إرتفاع مرضى نوع الخلية بي غير الناضجة من سرطان الدم الليمفاوي الحاد هم أصغر سنَا مع أعلى نس
. و قد أظهر التوزيع الجغرافي لحالات سرطان الدم الليمفاوي الحاد عند الأطفال حدثت سنوات 1و  5بين 
  
و لكن بنسبة متساوية للحالات التي شخصت  في محافظة الخليل %7..4ت و بنسبة تقريبا في نصف الحالا
 . في محافظة بيت لحم اعتمادا على التعداد السكاني للمحافظتين
) من نوع خلية بي غير الناضجة من %3.33حالة  ( 40و أظهر تحليل النمط الظاهري المناعي أن هناك 
حالات من نوع الخلية بي الناضجة من سرطان الدم الليمفاوي الحاد,  سرطان الدم الليمفاوي الحاد, عدم وجود
 ) من نوع الخلية تي من سرطان الدم الليمفاوي الحاد. %7..( حالة واحدةو وجود 
لقد وجدنا أن نسب التجانس فقط موجودة في نوع الخلية بي غير الناضجة من سرطان الدم الليمفاوي الحاد  
. فكانت نسبة ) على خلاياها المنفجرة33DC,31DCن المضادات النخاعية (بوجود واحدة أو إثنتان م
في حالات نوع الخلية بي غير الناضجة من سرطان الدم  %0.7ين النخاعين بنسبة التجانس لكلا المضاد
 الليمفاوي الحاد.
فوجدنا ن العلاج. اية المرحلة التعريفية ملقد فحصنا عدم وجود الحد الأدنى من خلايا المرض المتبقية في نه
 يوم 33أي بعد  من المرضى تعرضوا لاختفاء كامل للمرض بعد المرحلة التعريفية من العلاج %7..0انه 
من حالات سرطان الدم  %7.10سرطان الدم الليمفاوي الحاد من نوع تي, و  الحالة الوحيدة من بحيث يشمل
 .لالة احصائيةلكن بدون د الليمفاوي الحاد من نوع خلية بي غير الناضجة
 
 
عن النمط الظاهر المناعي لحالات سرطان الدم الليمفاوي  واضحة أن هذه الدراسة المميزة تقدم فكرة: الملخص
الضفة الغربية في فلسطين, و هذا  جنوب في من خلال تجربة مركز سرطان واحد يقع الحاد عن الأطفال
المتقدمة. أظهر التوزيع العمري أن حدوث الذروة كان  التوزيع كان شبيه لنمط التوزيع بشكل عام كما في الدول
  
سنوات لحالات سرطان الدم الليمفاوي الحاد من نوع الخلية بي غير الناضجة كما في البلدان  1و  5ما بين 
و قد أظهر التوزيع الجغرافي لحالات سرطان الدم الليمفاوي الحاد عند الأطفال حدثت تقريبا في  المتقدمة.
في محافظة الخليل و لكن بنسبة متساوية للحالات التي شخصت في  %7..4و بنسبة  نصف الحالات
 محافظة بيت لحم اعتمادا على التعداد السكاني للمحافظتين. 
بسبب أن عدم لمرضى سرطان الدم الليمفاوي الحاد كان جيد جدأ كما في الدول المتقدمة   الأستجابة للعلاج
بنسبة  كان يوم من العلاج 33ض المتبقية عند النقطة التعريفية أي بعد وجود الحد الأدنى من خلايا المر 
 من مرضى سرطان الدم الليمفاوي الحاد. %7..0
